Stock Analiz

Orthofix Medical Inc. OFIX

Medical/Dental Instruments · IPO 1992 · data as of November 13, 2026

$7.17Market cap $292M
Open the interactive analysis →

Orthofix Medical Inc. (OFIX) is a healthcare company listed in the US with a market value of about $292M. In the twelve months to September 30, 2026 it had revenue of $835M and net income of -$45M, a net margin of -5.4%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 15% a year, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 88% below the current price.

About Orthofix Medical

Orthofix Medical is listed in the US and classified in medical/dental instruments, IPO year 1992. Revenue went from $402M in 2014 to $822M in 2025, growth of about 6.7% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 97% over three years (dilution for shareholders). It spends 8% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E14.1
P/FCF—
P/S0.3
P/B0.7
EV/EBITDA14.0
PEG—
Dividend yield0.00%
FCF yield-15.2%
Shareholder yield0.0%
Intrinsic value vs. price−88%

Growth and quality

Revenue growth (1 yr)2.9%
Revenue growth (5 yrs, per year)15.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-12.0%
ROIC (5-yr avg.)-8.1%
Profitable years (of last 10)4
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$835M$822M$799M$747M$461M$464M$407M$460M$453M$434M$410M
Net income-$45M-$92M-$126M-$151M-$20M-$38M$3M-$28M$14M$6M$3M
Free cash flow-$44M-$1M-$9M-$106M-$33M$690000$59M$13M$36M$24M$43M
EPS (diluted)$-1.11$-2.33$-3.30$-4.12$-0.98$-1.95$0.13$-1.51$0.72$0.34$0.17
Net margin-5.4%-11.2%-15.8%-20.3%-4.3%-8.3%0.6%-6.2%3.0%1.4%0.8%
ROIC—-10.1%-9.9%-15.4%-3.0%-1.9%-1.4%-4.5%5.1%10.9%6.3%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $10.00, 39% above the current price; targets range from $9.00 to $11.00; the consensus rating is “Buy”; expected EPS is $0.43 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Orthofix Medical stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 88% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Orthofix Medical pay a dividend?

Not currently.

Is Orthofix Medical a good stock to buy?

We do not give buy or sell advice. Orthofix Medical scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.